Prognostic value and functional consequences of cell cycle inhibitor p27Kip1 loss in medulloblastoma

Biomarker Research

Beryl A Hatton⁴  David W Ellison²  Amar Gajjar⁵  Marcel Kool³  Matthew Fero⁴  James M Olson¹ 

[1] Division of Pediatric Oncology, University of Washington/Children’s Hospital, 4800 Sand Point Way NE, Seattle, WA 98105, USA

[2] Department of Pathology, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis 38105, Tennessee

[3] Division of Molecular Genetics, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg 69120, Germany

[4] Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Mailstop D4-100, PO Box 19024, Seattle, WA 98109, USA

[5] Department of Oncology, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis 38105, Tennessee

关键词: Prognostic factors;    Mouse cancer models;    Cerebellum;    Sonic hedgehog;    p27^Kip1;    Medulloblastoma;   

Others  :  792045
DOI  :  10.1186/2050-7771-1-14

 received in 2012-12-21, accepted in 2013-02-17,  发布年份 2013

【 摘 要 】

Background

The cyclin-dependent kinase inhibitor p27^Kip1 functions during normal cerebellar development and has demonstrated tumor suppressor functions in mouse models of medulloblastoma. Because P27 loss is associated with increased proliferation, we assessed whether P27 absence in surgical medulloblastoma specimens correlated with response to therapy in pediatric patients enrolled in two large studies. Additionally, we examined the functional consequence of p27^Kip1 loss in the SmoA1 medulloblastoma model to distinguish whether p27^Kip1 reduces tumor initiation or slows tumor progression.

Findings

Analysis of 87 well-characterized patient samples identified a threshold of P27 staining at which significant P27 loss correlated with poor patient outcome. The same criteria, applied to a second test set of tissues from 141 patients showed no difference in survival between patients with minimal P27 staining and others, suggesting that P27 levels alone are not a sufficient prognostic indicator for identifying standard-risk patients that may fail standard therapy. These findings were in contrast to prior experiments completed using a mouse medulloblastoma model. Analysis of cerebellar tumor incidence in compound mutant mice carrying the activated Smoothened (SmoA1) allele that were heterozygous or nullizygous for p27^Kip1 revealed that p27^Kip1 loss did not alter the frequency of tumor initiation. Tumors haploinsufficient or nullizygous for p27^Kip1 were, however, more invasive and displayed a higher proliferative index, suggesting p27^Kip1 loss may contribute to SmoA1 medulloblastoma progression.

Conclusions

These studies revealed P27 loss affects medulloblastoma progression rather than initiation and that this putative biomarker should not be used for stratifying children with medulloblastoma to risk-based therapeutic regimens.

【 授权许可】

   
2013 Hatton et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Gilbertson RJ: Medulloblastoma: signalling a change in treatment. Lancet Oncol 2004, 5:209-218.
• [2]Carlotti CG Jr, Smith C, Rutka JT: The molecular genetics of medulloblastoma: an assessment of new therapeutic targets. Neurosurg Rev 2008, 31:359-368. discussion 368–9
• [3]Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006, 7:813-820.
• [4]Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ: The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998, 396:177-180.
• [5]Bhatia B, Malik A, Fernandez-L A, Kenney AM: p27Kip1, A double-edged sword in Shh-mediated medulloblastoma. Cell Cycle 2010, 9:4307-4314.
• [6]Blain SW, Scher HI, Cordon-Cardo C, Koff A: p27 As a target for cancer therapeutics. Cancer Cell 2003, 3:111-115.
• [7]Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW: p27kip1: a multifunctional cyclin dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999, 154:313-323.
• [8]Adesina AM, Dunn ST, Moore WE, Nalbantoglu J: Expression of p27kip1 and p53 in medulloblastoma: relationship with cell proliferation and survival. Pathol Res Pract 2000, 196:243-250.
• [9]Schiffer D, Bortolotto S, Bosone I, Cancelli I, Cavalla P, Schiffer P, Piva R: Cell-cycle inhibitor p27/Kip-1 expression in non-astrocytic and non-oligodendrocytic human nervous system tumors. Neurosci Lett 1999, 264:29-32.
• [10]de Haas T, Hasselt N, Troost D, Caron H, Popovic M, Zadravec-Zaletel L, Grajkowska W, Perek M, Osterheld MC, Ellison D, Baas F, Versteeg R, Kool M: Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression. Clin Cancer Res 2008, 14:4154-4160.
• [11]Pizer BL, Weston CL, Robinson KJ, Ellison DW, Ironside J, Saran F, Pizer BL, Weston CL, Robinson KJ, Ellison DW, Ironside J, Saran F, Lashford LS, Tait D, Lucraft H, Walker DA, Bailey CC, Taylor RE: Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into SIOP/UKCCSG PNET 3 study. Eur J Cancer 2005, 42:1120-1128.
• [12]Taylor RE, Bailey CC, Robinson KJ, Weston CL, Walker DA, Ellison D, Ironside J, Pizer BL, Lashford LS: Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 2005, 41:727-734.
• [13]Marino S: Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 2005, 11:17-22.
• [14]Ayrault O, Zindy F, Rehg J, Sherr CJ, Roussel MF: Two tumor suppressors, p27Kip1 and patched-1, collaborate to prevent medulloblastoma. Mol Cancer Res 2009, 7:33-40.